Effective and Economical, Yet Sidelined: Unpacking Why American Medicine Keeps Choosing Costlier Alternatives to Chloroquine
In American medicine, the assumption that newer means better is so deeply embedded that it rarely requires justification. A drug approved decades ago, priced at a fraction of its successors, and supported by a substantial body of clinical literature might seem like an obvious first-line choice. Yet chloroquine — a compound that fits precisely that description — continues to lose ground in clinical practice to alternatives that are significantly more expensive, often no more effective, and in some cases less well understood over the long term. The question worth asking is not simply why this is happening, but who benefits when it does.
A Drug With a Long and Largely Favorable Record
Chloroquine phosphate has been in clinical use since the 1940s. Its applications span malaria prophylaxis and treatment, systemic lupus erythematosus (SLE), rheumatoid arthritis, and a growing list of off-label indications supported by emerging research. Across these uses, it has accumulated a pharmacological profile that most pharmaceutical developers would consider enviable: predictable absorption, well-characterized metabolism, a manageable side effect profile when monitored appropriately, and a cost that places it firmly within reach of most patients — including those without comprehensive insurance coverage.
Generic chloroquine is available in the United States for as little as a few dollars per month in some pharmacy discount programs. Compare that to hydroxychloroquine, its structural cousin, which typically costs more, or to newer biologic agents used in autoimmune conditions, which can run into the thousands of dollars monthly. The arithmetic alone should prompt questions about prescribing trends. Yet the arithmetic, it turns out, is rarely the deciding factor.
What the Clinical Evidence Actually Says
The clinical literature does not offer a straightforward verdict that newer agents are categorically superior to chloroquine. In SLE management, for instance, antimalarials including chloroquine have demonstrated meaningful reductions in disease flares, organ damage accumulation, and mortality. A number of rheumatologists who spoke to ChloroquineAV noted that in their clinical experience, patients who are adherent to chloroquine therapy and appropriately monitored for ocular toxicity often achieve disease control comparable to those on costlier regimens.
In malaria prevention, chloroquine remains effective in regions where resistance has not emerged, including parts of Central America, the Caribbean, and the Middle East. For travelers to those destinations, guidelines from the Centers for Disease Control and Prevention continue to list chloroquine as an appropriate prophylactic option. Yet anecdotal reports from travel medicine clinics suggest that prescribers frequently default to alternatives — mefloquine, atovaquone-proguanil, or doxycycline — without a clear clinical rationale tailored to the individual patient's destination or health profile.
The evidence, in other words, does not tell the story of a drug that has been scientifically surpassed. It tells the story of a drug that has been administratively and commercially deprioritized.
The Pharmaceutical Incentive Structure
To understand why clinicians reach for costlier alternatives, it is necessary to examine the environment in which prescribing decisions are made. Pharmaceutical manufacturers invest heavily in continuing medical education, clinical detailing, and conference sponsorship. Generic drugs, including chloroquine, generate minimal profit margins and therefore attract minimal promotional investment. A drug that no one is marketing is a drug that no one is thinking about at the point of prescribing.
Health economists who study pharmaceutical markets have long documented this dynamic. When a branded or newer agent enters a therapeutic category, it arrives with marketing infrastructure, clinical liaison teams, and speaker bureau programs that shape physician familiarity and comfort. Chloroquine, by contrast, has no manufacturer with an economic stake in its continued use. Its advocates are largely academic clinicians, patient advocates, and researchers — voices that carry weight in journals but considerably less in the commercial ecosystem that shapes day-to-day clinical behavior.
One health economist, speaking on background, described the situation bluntly: "The question isn't whether chloroquine works. It's whether anyone is being paid to remind doctors that it works. And the answer to that second question is no."
The Patient Perspective
For patients, the consequences of this market-driven displacement are concrete and sometimes severe. A lupus patient whose insurer requires step therapy before approving a biologic may spend months cycling through alternatives before receiving authorization. A patient without insurance navigating a rheumatology office where chloroquine is rarely discussed may leave with a prescription for a medication that costs hundreds of dollars more per month than a clinically viable alternative.
Patient advocates interviewed for this article described a consistent pattern: patients who ask their physicians about chloroquine are frequently met with uncertainty or mild discouragement, not because of documented clinical inferiority, but because the drug exists outside the prescribing habits that have been cultivated over years of commercial influence. "I had to bring the research to my own doctor," said one lupus patient in her mid-forties from the Chicago area. "She wasn't dismissive, but she clearly hadn't thought about chloroquine as a real option for me. That gap shouldn't exist."
The Role of Clinical Guidelines and Institutional Inertia
Clinical guidelines issued by professional societies play an enormous role in shaping prescribing behavior. When guidelines emphasize newer agents — sometimes based on industry-funded trials — older drugs may fade from clinical consciousness even in the absence of evidence that they should. Guidelines are not infallible documents; they reflect the state of published evidence, the composition of guideline committees, and the funding landscape of the research that informs them.
Rheumatologists and infectious disease specialists interviewed for this piece acknowledged that guideline language around chloroquine has sometimes been more cautious than the underlying evidence strictly warrants. The retinal toxicity concern, which is real and requires monitoring, has in some cases been communicated in ways that overstate risk relative to benefit — particularly for patients at lower doses and with regular ophthalmologic follow-up.
Institutional inertia compounds the problem. Once a drug falls out of routine use, training programs stop emphasizing it, electronic health record systems may not flag it as a default option, and the clinical muscle memory required to prescribe it confidently atrophies across a generation of practitioners.
What Patients and Clinicians Can Do
The appropriate response to this dynamic is not uncritical enthusiasm for chloroquine, nor reflexive skepticism about all newer agents. It is a commitment to evidence-based decision-making that is genuinely independent of commercial influence. For clinicians, that means periodically revisiting the literature on chloroquine across its approved and off-label indications, particularly when treating patients for whom cost or tolerability of alternatives is a concern.
For patients, it means arriving at clinical conversations prepared to ask direct questions: Is chloroquine an option for my condition? If not, what is the clinical reason — and is that reason documented in the evidence, or is it a matter of habit? These are reasonable questions, and they deserve substantive answers.
The paradox at the center of this story is not complicated. A drug that works, costs little, and has a well-understood safety profile is being systematically passed over in favor of alternatives that are more expensive and, in many cases, no better. That is not a clinical outcome. It is a market outcome. And in a healthcare system where patients bear real financial consequences for prescribing decisions, the distinction matters enormously.
